Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

HCV-Related Liver Cancer Incidence Dropped in US Cohort HCV-Related Liver Cancer Incidence Dropped in US Cohort
The incidence of hepatocellular carcinoma declined after widespread use of direct-acting antiviral therapies to treat hepatitis C, according to findings from a large population-based study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Steatohepatitis Biomarkers and HCC After HCV Elimination Steatohepatitis Biomarkers and HCC After HCV Elimination
This study used steatohepatitis-related biomarkers to evaluate the development of hepatocellular carcinoma by patients with chronic hepatitis C who achieved SVR by DAA treatment.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Chemotherapy drug more effective when combined with microbubbles
(American Institute of Physics) Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Sex Disparities in Presentation and Prognosis of HCC Sex Disparities in Presentation and Prognosis of HCC
A new study examines the sex disparities that exist in hepatocellular carcinoma presentation and prognosis. In what ways might these differences impact outcomes?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Yilmaz Mahshid takes office as CEO of Medivir on 14 September
STOCKHOLM, Aug. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who has been CEO since October 2018, wil... Biopharmaceuticals, Oncology, Personnel Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 18, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

SVR From DAA, Interferon-based Treatments for HCV and HCC Risk SVR From DAA, Interferon-based Treatments for HCV and HCC Risk
How does sustained virologic response from direct-acting antiviral and interferon-based treatments impact the risk of developing hepatocellular carcinoma?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 5, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Pembrolizumab too costly as 2nd-line therapy of hepatocellular carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2020 Category: Drugs & Pharmacology Source Type: news

HCC in Chronic HCV Patients Who Achieved SVR HCC in Chronic HCV Patients Who Achieved SVR
Does achieving SVR with DAAs reduce the incidence of hepatocellular carcinoma in chronic hepatitis C patients, genotype IV with liver cirrhosis and advanced hepatic fibrosis?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 17, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Sequential Systemic Treatment in Patients With HCC Sequential Systemic Treatment in Patients With HCC
This study investigated the feasibility and efficacy of sequential systemic treatments with currently available and recently approved drugs for the treatment of hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

Viral Exposure Signature Predicts Hepatocellular Carcinoma
Signature can identify hepatocellular carcinoma patients before clinical diagnosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 10, 2020 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Oncology, Pathology, Journal, Source Type: news

Viral Exposure Signature Predicts Hepatocellular Carcinoma
FRIDAY, July 10, 2020 -- A viral exposure signature can predict hepatocellular carcinoma (HCC) risk before clinical diagnosis among at-risk patients, according to a study published online June 10 in Cell. Jinping Liu, Ph.D., of the National Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 10, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Tripl...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news

New Blood Test May Improve Liver Cancer Screening
The test checks people for previous exposure to certain viruses that may interact with the immune system and increase the risk of hepatocellular carcinoma (HCC), according to their new study. (Source: WebMD Health)
Source: WebMD Health - June 17, 2020 Category: Consumer Health News Source Type: news

Deep learning detects HCC on contrast-enhanced MRI
A deep-learning algorithm can detect hepatocellular carcinoma (HCC) on contrast-enhanced...Read more on AuntMinnie.comRelated Reading: Functional, diffusion MRI could benefit from AI MRI identifies biomarkers for aggressive HCC subtype CE-MRI with CT extends life for patients with liver cancer AI tops recent imaging informatics highlights Beyond the black box? AI algorithm explains decisions (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 12, 2020 Category: Radiology Source Type: news

Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective
Paper proposes treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (i.e. 0, A, B,& C), specifically in relation to surgery, locoregional therapies, and systemic therapy. It also suggests strategies to modify risk during pandemic. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 12, 2020 Category: Consumer Health News Source Type: news

NIH scientists develop blood test to help improve liver cancer screening
Test can help identify people likely to develop hepatocellular carcinoma, the most common form of liver cancer (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - June 11, 2020 Category: American Health Source Type: news

NIH scientists develop blood test to help improve liver cancer screening
(NIH/National Cancer Institute) Scientists have developed a new test that can help identify people who are likely to develop hepatocellular carcinoma (HCC), the most common form of liver cancer. The approach uses a simple blood test to check for the patient's previous exposure to certain viruses. The findings were published June 10 in Cell. A study of the new approach was led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2020 Category: Cancer & Oncology Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received p rior systemic therapy.“We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph....
Source: Roche Media News - June 2, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 2, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
South San Francisco, CA -- May 29, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) in combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 29, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Atezolizumab/Bevacizumab Combination for HCC
The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Medivir Appoints Yilmaz Mahshid as New CEO
STOCKHOLM, May 26, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company. Yilmaz Mahshid has long and broad experience f... Biopharmaceuticals, Oncology, Personnel Medivir AB, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 26, 2020 Category: Pharmaceuticals Source Type: news

Liver cancer: Awareness of hepatitis D must be raised
(Universit é de Gen è ve) Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma. They demonstrated that people infected with Hepatitis D have up to three times the risk of developing that particularly aggressive and often fatal liver cancer compared to those infected only with Hepatitis B. These results, to be read in the Journal of Hepatology, plead for systematic screening of Hepatitis D in patients with Hepatitis B. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2020 Category: International Medicine & Public Health Source Type: news

' Momentous' Data for First-Line Combo in Liver Cancer'Momentous' Data for First-Line Combo in Liver Cancer
The combination of atezolizumab and bevacizumab for the first-line treatment of unresectable hepatocellular carcinoma is set to become the new standard of care for this poor-prognosis cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New treatment extends lives of people with most common type of liver cancer
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.Researchers found that a  combination of atezolizumab, an immunotherapy drug that boosts the body ’s natural defenses, and bevacizumab, an anti-angiogenesis drug that inhibits the growth of tumors’ blood vessels, improved overall survival and reduced the risk of death by 42%. It also decreased the risk of the disease worsening by 41%, and the percentage of patients whose cancer shrank or disappeared more th...
Source: UCLA Newsroom: Health Sciences - May 13, 2020 Category: Universities & Medical Training Source Type: news

Atezolizumab-Bevacizumab Beats Sorafenib in Liver Cancer
WEDNESDAY, May 13, 2020 -- Atezolizumab plus bevacizumab improves survival outcomes versus sorafenib in patients with unresectable hepatocellular carcinoma, according to a study published in the May 14 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2020 Category: Pharmaceuticals Source Type: news

New treatment extends lives of people with most common type of liver cancer
(University of California - Los Angeles Health Sciences) For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 13, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer. Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients. Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb. The study is being cond...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Thermal Ablation for Hepatocellular Carcinoma: What's New Thermal Ablation for Hepatocellular Carcinoma: What's New
Get up-to-date on the latest developments and new advancements in the use of thermal ablation for the treatment of hepatocellular carcinoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818
STOCKHOLM, April 30, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has received positive opinion from the Committee for Orphan Medicinal Products on orphan medicinal product designation in t... Biopharmaceuticals, Oncology, Regulatory Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2020 Category: Pharmaceuticals Source Type: news

New study indicates exercise can help prevent liver cancer
(Elsevier) Liver cancer is the fourth most common cause of cancer death worldwide and is growing rapidly due to the 'diabesity pandemic.' A new study reported in the Journal of Hepatology, published by Elsevier, provides strong evidence that voluntary exercise could help prevent the most common type of liver cancer, hepatocellular carcinoma, and identifies the molecular signaling pathways involved. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2020 Category: Cancer & Oncology Source Type: news

Sugar, Fat, Alcohol … What’s Worse for the Liver?
This webinar will investigate the increasing mortality rates of liver disease in the UK associated with obesity and the excess consumption of alcohol. It will give an overview of non-alcoholic fatty liver disease (NAFLD), which is now the most common  of liver disease affecting an estimated 25-30% of adults and 10% of children in the UK and worldwide. Both NAFLD and alcohol-related fatty liver can progress to severe liver disease including fibrosis, cirrhosis and hepatocellular carcinoma. The roles of genetics, obesity and dietary patterns i n the development and progression of liver disease will be dis...
Source: The Nutrition Society - April 9, 2020 Category: Nutrition Authors: Jade Mitchell Source Type: news

Low-Dose Aspirin May Lower Risk of Hepatocellular Carcinoma & amp; Liver-Related Mortality
A nationwide study found that low-dose aspirin was associated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality compared to no aspirin use, without a significantly higher risk of gastrointestinal bleeding. (Source: CancerNetwork)
Source: CancerNetwork - March 16, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Risk for Liver Cancer Down With Low-Dose Aspirin in Hepatitis B, C
WEDNESDAY, March 11, 2020 -- Low-dose aspirin is associated with a reduced risk for hepatocellular carcinoma among patients with chronic viral hepatitis, according to a study published in the March 12 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Immunotherapy Combo for Liver Cancer FDA Approves Immunotherapy Combo for Liver Cancer
Nivolumab and ipilimumab together produce a response rate double that of nivolumab alone in advanced hepatocellular carcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

U.S. Food and Drug Administration approves Opdivo ® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
Bristol Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib.1,2 Approval for this indication has been granted under accelerated approval based on (Source: World Pharma News)
Source: World Pharma News - March 11, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

FDA Approves Nivolumab-Ipilimumab Combo for Hepatocellular Carcinoma
The FDA approved the combination use of nivolumab plus ipilimumab for the treatment of patients with HCC who have been previously treated with sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - March 11, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Levels of sBTLA proteins as potential marker of overall survival of liver cancer patients
(Osaka City University) Researchers at Osaka City University Graduate School of Medicine introduced sorafenib to patients with advanced stages of the liver cancer hepatocellular carcinoma (HCC) and measured the amount of 16 circulating soluble immune checkpoint proteins. Their data suggest that a high amount of sBTLA proteins may be a marker of overall survival in patients with HCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 9, 2020 Category: Cancer & Oncology Source Type: news

FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma
Basel, 4 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys ® GALAD score.* This algorithmic score combines gender and age with the biomarker results of the Elecsys AFP, AFP-L3 and PIVKA-II and is intended to aid diagnosis of early stage hepatocellular carcinoma (HCC). Dr. Amit Singal, Medical Director of the Liver Tumor Program   and Clinical Chief of Pathology at UT Southwestern Medical Center in Dallas, USA, stated, " HCC is the fourth leading cause of cancer-related death worldwide, wit...
Source: Roche Media News - March 4, 2020 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma
Basel, 4 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys ® GALAD score.* This algorithmic score combines gender and age with the biomarker results of the Elecsys AFP, AFP-L3 and PIVKA-II and is intended to aid diagnosis of early stage hepatocellular carcinoma (HCC). Dr. Amit Singal, Medical Director of the Liver Tumor Program   and Clinical Chief of Pathology at UT Southwestern Medical Center in Dallas, USA, stated, " HCC is the fourth leading cause of cancer-related death worldwide, wit...
Source: Roche Investor Update - March 4, 2020 Category: Pharmaceuticals Source Type: news

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma
FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Liver Transplantation for Hepatocellular Carcinoma Liver Transplantation for Hepatocellular Carcinoma
This article presents a comprehensive review of current knowledge regarding the posttransplant management of patients with hepatocellular carcinoma.American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2020 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

From obesity to liver cancer: Can we prevent the worst?
(Universit é de Gen è ve) Hepatocellular carcinoma, a liver cancer linked to the presence of fat in the liver, is one of the leading causes of cancer death worldwide. Scientists (UNIGE) have discovered a protein involved in the progression of a " fatty liver " towards cancer. This protein could allow early detection of the risk of developing liver cancer and open the way to new targeted therapies. These results highlight the close links between our diet and cancer development. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news